Bioanalysis Zone and Bioanalysis welcome unsolicited submissions to both the journal and website!
From novel analytical instrumentation to the recent developments in the bioanalysis of biopharmaceuticals and biomarkers, as the New Year starts we’re looking back on the bioanalytical highlights from 2017.
A Swedish research team has identified a method of drug and disease detection through the analysis of various compounds in exhaled breath.
We interviewed Shalini Prasad and Sriram Muthukumar about their new technology, termed EnLiSense LLC, that specializes in sensor technologies for enhancing lifestyle decisions.
At Reid 2017 we interviewed Jennifer Hincks, Principal Scientist at LGC, about her role in setting up a new flow cytometry service. Jennifer discusses her passion for flow cytometry, how it can be used to analyze biomarkers and how this field can be regulated and standardized.
At Reid 2017 we interviewed James Rudge, Global Microsampling Specialist at Neoteryx, about his role in developing volumetric absorptive microsampling. James talks about his interest in biomarkers, what technologies he uses to analyze biomarkers and how he thinks the ‘omics’ field will come online.
Neil Henderson discusses his experiences with oligonucleotides, the technologies that he uses and his work as part of the Translational Biomarker and Bioanalysis group at Astrazeneca.
Researchers have identified an alternative method to biopsies that could measure a patient’s response rate to immunotherapies utilizing the PD-1 pathway.
A new genetic test has been discovered by researchers that could help predict cancer recurrence and lead the way to personalized treatment.
Through metabolic fingerprinting researchers have identified specific compounds that could be utilized as biomarkers for smoking induced biological changes.